TB-500 UK status in three parts: the law, WADA and the research

Written by Free Muscle · Published by a seller of these compounds · Last updated

TB-500's UK status is not settled by any regulator page we could cite: it depends on how the Human Medicines Regulations 2012 define a medicinal product and on how the product is presented and sold, while a 2023 anti-doping study states that thymosin beta-4 is on the World Anti-Doping Agency prohibited list. A TB-500 UK search tends to raise three questions at once: what does UK law say, does the World Anti-Doping Agency prohibit it, and what has the published research actually found? This guide takes each in turn. It sets out what the Human Medicines Regulations 2012 say about medicinal products, what the anti-doping literature reports about thymosin beta-4 and TB-500, what the published studies cover and where they fall short, what "research use only" actually means, what could not be verified, and how to read a Certificate of Analysis. It is general information, not legal advice, and it is not medical advice. Listings (laboratory research only, 18+): TB-500 capsules compared.

Key takeaways

  • TB-500 is the name given to a synthetic peptide, an acetylated fragment of thymosin beta-4 (residues 17 to 23), that has been described in veterinary and doping-control literature (Ho et al., 2012; Esposito et al., 2012).
  • No UK regulator page ruling on TB-500 by name is cited in this guide. Its status depends on how the Human Medicines Regulations 2012 define a medicinal product and on how a substance is presented and sold.
  • A 2023 anti-doping study states that thymosin beta-4 is on the World Anti-Doping Agency prohibited list (Rahaman et al., 2023), and TB-500 has been the subject of doping-control detection work. Athletes should check with UK Anti-Doping directly.
  • "Research use only" is a statement about the intended setting for a material. It does not make a product a medicine, a food supplement or fit for human consumption.
  • A Certificate of Analysis is only as good as its details: a named independent laboratory, a batch number that matches the label, a date, and identity and purity data.
  • Most published work on thymosin beta-4 and TB-500 concerns injection, cell culture or animals. Nothing in the records reviewed here tested an oral capsule.

There is no simple yes or no to the TB-500 UK legal question, and anyone who offers one without citing the law should be treated cautiously. What can be done is to set out what the primary legislation says and what could not be confirmed. This is general information, not legal advice; a solicitor can advise on a specific situation.

What the Human Medicines Regulations 2012 say

The starting point is the definition of a medicinal product. Under regulation 2 of the Human Medicines Regulations 2012, the term covers any substance that may be used by or administered to human beings with a view to restoring, correcting or modifying a physiological function through a pharmacological, immunological or metabolic action. It also covers anything presented as having properties for treating or preventing disease. Two limbs, then: what a substance does, and how it is presented.

Two further rules follow from that definition. Regulation 46 states that a person may not sell or supply, or offer to sell or supply, an unauthorised medicinal product, and lists the authorisations that would make a sale lawful: a UK marketing authorisation, a certificate of registration, a traditional herbal registration or an Article 126a authorisation. Regulation 17 says that a person may not, except in accordance with a manufacturer's licence, manufacture or assemble a medicinal product, or import one into Great Britain from a country other than Northern Ireland or an approved country for import.

What could not be confirmed

No Medicines and Healthcare products Regulatory Agency (MHRA) page classifying TB-500 is cited in this guide; the only MHRA material used is a general October 2023 notice about fake weight-loss pens, which says prescription-only medicines should be obtained on prescription. That notice is about different products and is not a ruling on TB-500. It is cited only as general MHRA context on prescription-only medicines.

PubMed searches run on 2 October 2026 found no report of clinical development of the TB-500 fragment and no human trial of it. PubMed is not a register of authorised medicines, and this guide did not search one; absence of a publication is not a legal conclusion.

Practical reading

In plain terms, whether a particular listing falls inside the medicinal-product definition is understood to turn on the factors in regulation 2: what a substance does (its pharmacological, immunological or metabolic action) and how it is presented. The regulations do not mention TB-500 by name, and whether a given listing falls within the definition is a legal question this guide does not answer. If you need certainty about a specific purchase, take professional legal advice rather than relying on a blog, including this one.

The position for the other compounds we stock, side by side: Are SARMs legal in the UK? 2026 guide

What "research use only" means, and what it does not

The phrase "research use only" describes the setting a material is intended for. Whether a product falls within the medicinal-product definition is a separate question, covered in the section above.

What it means

  • The material is sold for laboratory research use only and is not for human consumption.
  • The buyer is expected to be an adult, and Free Muscle sells its research compounds only to customers aged 18 or over.
  • Free Muscle describes the material as not a medicine and not a food supplement.

What it does not mean

  • It does not mean a material has been tested in people or approved by any regulator.
  • It does not mean the label alone guarantees identity or purity; that is the job of independent testing, covered below.
  • It does not answer whether a substance is permitted in sport. That is set by anti-doping rules, which this guide does not reproduce.
  • It does not settle the legal question in the section above. A label describes intent; the regulations look at function and presentation.

On format: the Free Muscle listing for TB-500 Thymosin Beta-4, 60 capsules describes capsules and does not state the strength. The literature distinguishes two molecules: full-length thymosin beta-4 (43 amino acids; Guarnera et al., 2010) and the short acetylated TB-500 fragment (Ho et al., 2012), which is why identity testing matters.

What the published research says

This section summarises the published record on TB-500 and thymosin beta-4 as an educational overview for a TB-500 UK reader. Every finding below describes what happened to a named study population in a named study, and results from injection, cell culture or animals cannot be assumed to apply to an oral capsule. Anecdotal reports are not evidence and are not used here.

Anti-doping literature

A 2012 analytical study found the acetylated 17 to 23 fragment of human thymosin beta-4 in a product sold as TB-500, using liquid chromatography and high-resolution mass spectrometry, and described the formulation as suspected of being used as a doping agent in sport (Esposito et al., 2012). A veterinary doping-control study the same year detected the acetylated peptide and its metabolites in plasma and urine from horses given a single administration of a TB-500 preparation (Ho et al., 2012). Its detection limits were very low: 0.02 ng/mL in plasma and 0.01 ng/mL in urine.

A 2023 laboratory and rat study developed a urine test for a metabolite of thymosin beta-4 and noted that thymosin beta-4 is listed as a prohibited substance by the World Anti-Doping Agency (Rahaman et al., 2023). In those rats the metabolite could be measured for up to 48 hours and was highest in the first six hours, and it was absent from untreated controls, including a human blank urine sample. This guide relies on that secondary statement: the WADA website itself could not be read when the sources were gathered, so the exact wording of the current list was not verified. Whether a substance is permitted in sport is set by anti-doping rules, which this guide does not reproduce; athletes should read the current list at WADA and ask UK Anti-Doping.

Animal data on TB-500

The only study in the records that carries the TB-500 name in its efficacy design is a 2026 rat Achilles tendon study (Biçer et al., 2026). It used 32 rats in four groups of eight, with tendon transection and repair, and followed the rats for four weeks after surgery; the treatment protocol is given in the paper. At four weeks, maximum load to failure was higher in the TB-500 group than in controls (p < 0.05), and tendon scores were lower in that group (Bonar p = 0.016; Movin p = 0.017), which the authors described as less degenerative change. A combination with another peptide added no further benefit. The authors called the work exploratory and preliminary, and said dose optimisation and longer studies were still needed. The abstract describes TB-500 as synthetic thymosin beta-4, so it is not clear that the molecule tested was the 17 to 23 fragment.

Human trials of full-length thymosin beta-4

No human trial of the TB-500 fragment was found. The human trials found in the records reviewed here used full-length thymosin beta-4, by intravenous, topical or eye-drop routes:

  • A randomised, placebo-controlled phase I study studied intravenous synthetic thymosin beta-4 in four cohorts of 10 healthy volunteers, who received placebo or the peptide. Adverse events were infrequent and mild or moderate, with no dose-limiting toxicity or serious adverse events (Ruff et al., 2010).
  • A first-in-human phase I study of a recombinant form enrolled 54 healthy volunteers in a single-dose part and 30 in a multiple-dose part, and also reported mild to moderate adverse events and no serious ones (Wang et al., 2021).
  • A phase II eye-drop trial in 72 people with dry eye found no significant difference on either primary endpoint, although a secondary measure of discomfort was 27% lower than placebo (P = 0.0244) (Sosne and Ousler, 2015).
  • A phase II topical study in 73 patients with venous ulcers judged the safety profile acceptable and comparable to placebo; the authors said one concentration may have the potential to accelerate healing, and reported complete healing within three months in about 25% of patients. The abstract does not report how that figure compared with placebo (Guarnera et al., 2010).

These trials reported only the outcomes in their abstracts, none involved oral administration or athletic outcomes, and long-term safety was not addressed in those abstracts.

Findings that point the other way

A balanced reading includes the negative and cautionary results. In pigs undergoing heart surgery with bypass, systemic thymosin beta-4 did not reduce cell death or change cardiac function; at high doses in laboratory tests the authors saw effects on blood vessels and reduced clot firmness in the presence of an antiplatelet agent (Stark et al., 2016). Cell and tissue work has also raised a theoretical cancer-related question. Overexpression of thymosin beta-4 increased migration of colon cancer cells in culture (Tang et al., 2011), and immunoreactivity for thymosin beta-4 was detected in 59 of 76 colorectal carcinomas in a retrospective tissue study, although mRNA differences between tumour and normal mucosa were not significant (Nemolato et al., 2012). Those are expression and cell studies, not trials of an administered peptide, so they show a question rather than an answer.

What the 2026 reviews conclude

A 2026 narrative review of approved and unapproved peptides, including thymosin beta-4 and TB-500, said many unapproved peptides show favourable tissue-repair results in animals while rigorous human safety data are scarce, and it described a "gray market" operating largely outside regulatory oversight (Mendias and Awan, 2026). A 2026 scoping review found that 67% of the identified publications on six peptides, including TB-500, used animal models, and concluded that claimed musculoskeletal benefits remain unsubstantiated by current human trials (Tewari et al., 2026). Both reviews are a reason for caution about marketing claims of any kind.

How to judge quality: the Certificate of Analysis explained

A Certificate of Analysis, or COA, is a report from a laboratory describing what it measured in a specific batch. A 2026 review described a "gray market" of unapproved peptides operating largely outside regulatory oversight (Mendias and Awan, 2026). Separately, an independent COA is one practical way to check what a batch contains; this is general laboratory practice, not a finding of that review. The label "TB-500" has been applied to the 17 to 23 fragment, while the literature separately discusses the full 43 amino acid protein; those are different molecules. Two techniques do most of the work. HPLC (high-performance liquid chromatography) separates a sample into its components, so the size of the main peak against the others indicates purity. Mass spectrometry measures the mass of the molecules, which confirms identity. The analytical studies cited above used liquid chromatography coupled to mass spectrometry to detect and identify the peptide (Esposito et al., 2012; Ho et al., 2012). The descriptions of HPLC and mass spectrometry here are general laboratory background, not findings of those studies. For more detail, see the Free Muscle explainer on how to read a Certificate of Analysis.

The following checklist is general laboratory practice, not a finding of the studies cited here.

What to check What it tells you Red flag
Named laboratory Who did the testing, and whether they are independent of the seller No laboratory named, or a logo with no contact details or verification route
Batch number That the report describes the batch in your hands Batch number missing, or different from the one printed on the label
Test date That the report is recent and belongs to this production run No date, or a date that long predates the product
Identity by mass spectrometry Whether the measured mass matches the expected peptide (fragment versus full-length protein) No mass data, or a mass that fits a different molecule
Purity by HPLC The share of the sample accounted for by the main peak A purity figure with no chromatogram, or a perfectly round figure with no trace
Quantity per unit How much active material the report says is present Strength not stated anywhere, so totals cannot be worked out
Product name That the report covers the product listed, not a different one A generic report that never names the product

When reading any peptide listing, compare the batch number on the report with the label, character by character. Check also that the listing states strength per unit and unit count. The Free Muscle TB-500 listing is for 60 capsules, but its product page does not state the strength per capsule, so check the label and the Certificate of Analysis, and ask Free Muscle if neither gives a strength. A COA shows what was in a sample; it does not show how a product was stored afterwards, and it is not a statement that a material is suitable for any use in people.

How batch testing works at Free Muscle

Every Free Muscle batch of research compounds is assayed for identity and purity by Janoshik Analytical, an independent laboratory. Independent here means the testing is done by a separate organisation, not the seller. The Certificate of Analysis for a batch is sent on request: email the batch number printed on the label together with the product name. The process is described on the Free Muscle lab tests page, and the background on the laboratory is in the explainer what is Janoshik Analytical.

How to order from Free Muscle, step by step

These steps describe how a TB-500 UK order works at Free Muscle, based on the company's own pages.

  1. Choose the listing. Open the TB-500 listing or browse the wider peptides collection. Read the pack description.
  2. Age requirement. Research compounds are sold for laboratory research use only, to customers aged 18 or over.
  3. Delivery. UK delivery is free and tracked, in plain packaging, and takes 2 to 5 working days; details are on the shipping page.
  4. Check the label. When the parcel arrives, find the batch number printed on the label and keep it, and follow any storage statement on the label or the supplier's documents.
  5. Request the COA. Email the batch number and the product name to request the Certificate of Analysis for that batch, and file it with the batch number.
  6. Returns. Free Muscle's returns terms are on the guarantee page; check them before ordering.

Frequently asked questions

Is TB-500 legal in the UK?

No authority text found in the research for this TB-500 UK guide classifies TB-500 by name. Under the Human Medicines Regulations 2012, whether something is a medicinal product depends on its function and presentation, and selling an unauthorised medicinal product is prohibited by regulation 46. This is general information, not legal advice.

Is TB-500 banned by WADA or in sport?

This guide could not confirm from the WADA site how the current list treats TB-500 by name; the source cited here refers to thymosin beta-4. A 2023 anti-doping study states that thymosin beta-4 is on the World Anti-Doping Agency prohibited list (Rahaman et al., 2023), and TB-500 has been studied in doping-control work. The exact wording of the current list could not be verified from the WADA site, so athletes should check the list and ask UK Anti-Doping.

What do the law, WADA and the research each say about TB-500 in the UK?

On the law, no authority text found for this guide classifies TB-500 by name; under the Human Medicines Regulations 2012 the question turns on function and presentation. On anti-doping, a 2023 study states that thymosin beta-4 is on the World Anti-Doping Agency prohibited list (Rahaman et al., 2023), though the current wording could not be verified from the WADA site. On research, no human trial of the TB-500 fragment was found, and most evidence concerns injection, cell culture or animals, so it cannot be assumed to apply to an oral capsule. This is general information, not legal advice.

Is TB-500 the same as thymosin beta-4?

Not exactly. Thymosin beta-4 is a 43 amino acid protein. TB-500 as analysed in the doping literature is an acetylated fragment covering residues 17 to 23 (Ho et al., 2012). Identity testing is how a batch is checked against the molecule named on the label.

How do I check the purity of a batch?

Ask for the Certificate of Analysis and look for HPLC purity data and mass-spectrometry identity data from a named independent laboratory, with a batch number matching the label. Free Muscle batches are assayed by Janoshik Analytical; the lab tests page has further detail.

What are the ordering and delivery terms?

Research compounds are sold to customers aged 18 or over, with free tracked UK delivery in plain packaging. The shipping page and guarantee page give the details.

Has TB-500 been tested in human trials?

No human trial of the TB-500 fragment was found. Human trials of full-length thymosin beta-4 were found in the records reviewed here for intravenous, topical and eye-drop routes, and none tested an oral capsule. The 2026 scoping review concluded that claimed benefits remain unsubstantiated in humans (Tewari et al., 2026).

Sources

  1. Mendias CL, Awan TM. Safety and efficacy of approved and unapproved peptide therapies for musculoskeletal injuries and athletic performance. Sports Med. 2026;56(8):1921-1935. doi:10.1007/s40279-026-02437-0. PMID 41966639
  2. Tewari K, Liu TP, Im C, et al. Peptide supplements and their therapeutic applications in sports medicine. Am J Sports Med. 2026. doi:10.1177/03635465261464420. PMID 42578445
  3. Esposito S, Deventer K, Goeman J, Van der Eycken J, Van Eenoo P. Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500, a product suspected to possess doping potential. Drug Test Anal. 2012;4(9):733-8. doi:10.1002/dta.1402. PMID 22962027
  4. Ho EN, Kwok WH, Lau MY, et al. Doping control analysis of TB-500, a synthetic version of an active region of thymosin β₄, in equine urine and plasma by liquid chromatography-mass spectrometry. J Chromatogr A. 2012;1265:57-69. doi:10.1016/j.chroma.2012.09.043. PMID 23084823
  5. Rahaman KA, Muresan AR, Hasan ML, et al. Detection and quantification of the metabolite Ac-Tβ1-14 in in vitro experiments and urine of rats treated with Ac-Tβ4: A potential biomarker of Ac-Tβ4 for doping tests. Drug Test Anal. 2023;15(11-12):1454-1467. doi:10.1002/dta.3552. PMID 37515313
  6. Biçer O, Adanir O, Güleryüz Y, et al. Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study. Jt Dis Relat Surg. 2026;37(3):822-837. doi:10.52312/jdrs.2026.2951. PMID 42542926
  7. Ruff D, Crockford D, Girardi G, Zhang Y. A randomized, placebo-controlled, single and multiple dose study of intravenous thymosin beta4 in healthy volunteers. Ann N Y Acad Sci. 2010;1194:223-9. doi:10.1111/j.1749-6632.2010.05474.x. PMID 20536472
  8. Wang X, Liu L, Qi L, et al. A first-in-human, randomized, double-blind, single- and multiple-dose, phase I study of recombinant human thymosin β4 in healthy Chinese volunteers. J Cell Mol Med. 2021;25(17):8222-8228. doi:10.1111/jcmm.16693. PMID 34346165
  9. Sosne G, Ousler GW. Thymosin beta 4 ophthalmic solution for dry eye: a randomized, placebo-controlled, phase II clinical trial conducted using the controlled adverse environment (CAE™) model. Clin Ophthalmol. 2015;9:877-84. doi:10.2147/OPTH.S80954. PMID 26056426
  10. Guarnera G, DeRosa A, Camerini R. The effect of thymosin treatment of venous ulcers. Ann N Y Acad Sci. 2010;1194:207-12. doi:10.1111/j.1749-6632.2010.05490.x. PMID 20536470
  11. Stark CK, Tarkia M, Kentala R, et al. Systemic dosing of thymosin beta 4 ... does not attenuate global myocardial ischemia-reperfusion injury in pigs. Front Pharmacol. 2016;7:115 (title abridged). doi:10.3389/fphar.2016.00115. PMID 27199757
  12. Tang MC, Chan LC, Yeh YC, et al. Thymosin beta 4 induces colon cancer cell migration and clinical metastasis via enhancing ILK/IQGAP1/Rac1 signal transduction pathway. Cancer Lett. 2011;308(2):162-71. doi:10.1016/j.canlet.2011.05.001. PMID 21621326
  13. Nemolato S, Restivo A, Cabras T, et al. Thymosin β 4 in colorectal cancer is localized predominantly at the invasion front in tumor cells undergoing epithelial mesenchymal transition. Cancer Biol Ther. 2012;13(4):191-7. doi:10.4161/cbt.13.4.18691. PMID 22233609
  14. The Human Medicines Regulations 2012, regulations 2, 17 and 46. legislation.gov.uk.
  15. MHRA. MHRA warns of unsafe fake weight loss pens. gov.uk, 26 October 2023.

Notice. This article is published by Free Muscle, which sells the research compounds discussed. Research compounds sold by Free Muscle are supplied for laboratory research use only and are not for human consumption. They are not authorised as medicines by the MHRA, EMA or FDA, are not food supplements, and are sold only to adults aged 18 or over. Nothing on this page is medical or dosing advice. This is general information, not legal advice.

Related guides